Alaska Prescription Drug Monitoring Program
Summary Prepared for the State Medical Board
Q4 2021

This report contains summary data from the Prescription Drug Monitoring Program (PDMP). Data is provided as a courtesy for the board and is intended to be used for informational purposes only.

News as of February 16, 2022

- The PDMP fee was reduced to $0 and the PDMP Registration has been discontinued effective December 23, 2021. Registration status will be reflected on the professional license.
- We have hired an Occupational Licensing Examiner (OLE) to assist with the processing and migration of data as we implement changes in the licensing system.
- We are currently advertising for a Project Assistant to work on Reporting.
- License integration was successfully launched on January 11, 2022.
- The Communications module went live on February 8, 2022. Configurations are still be enabled and we expect to go live before March 2022.
- We are now data sharing with 17 states and the Military Health System. We recently started sharing with Arizona and Florida.
- We will begin conducting a delegate audit during the month of March. An announcement will be sent out through AWARxE and a guide will be made available next week on the PDMP website.

Registration

Portal

Physician Assistants
Number of licensed Physician Assistants: 731
Number of PDMP Physician Assistants registrations: 518
Number of Physician Assistants with DEA registrations: 782
Directly dispensing: 64

Physicians (includes Podiatrists and Medical Residents)
Number of licensed Physicians: 5,118
Number of PDMP Physicians registrations: 4,157
Number of Physicians with DEA registrations: 4,476
Directly dispensing: 203

AWARxE (PDMP)

Number registered with the PDMP: 4,836
- Physician: 4,164
- Physician Assistants: 619
- Medical Resident with Prescriptive Authority: 25
- Podiatrists: 28

Review

Federally scheduled II – III, over a three-day supply (some specialties omitted)

Physician Assistants
- Q3 2021: 51%
- Q4 2021: 46%

Physicians, Podiatrists, Medical Residents
- Q3 2021: 44%
- Q4 2021: 40%

Contact: Lisa Sherrell | PDMP Manager| akpdmp@alaska.gov | 907-465-1039

Recommendations

- Promote increased reviewing. Mandatory review applies to non-refillable federally scheduled II – III controlled substances over a three-day supply (for further exemptions see AS 17.30.200(k)).
- Encourage the option of using delegates to assist with reviews
- Provide guidance to licensees on prescribing practices related to the use of dangerous combinations
- Remind providers who are directly dispensing to report daily, including zero reports